Taiga Biotechnologies was founded to develop novel approaches to treat hematological diseases, including cancers, immunodeficiencies and autoimmune conditions. Our three-pronged approach combines novel breakthroughs in cellular, biologic and small molecule approaches to treat and manage these diseases.

Welcome to Taiga Biotechnologies.

Latest News

Taiga’s Scientific Advisory Board Chairman, Yosef Refaeli, is featured in a Nature article about the growing bioscience industry in the Denver area. Read the article.

March 1, 2010: Taiga Biotechnologies, Inc. received its third small business innovation research grant from the Department of Health and Human Services, National Institute of Allergy and Infectious Disease . The grant will be used to further develop the proprietary technology for improving vaccines for infectious disease and cancer with a new adjuvant product called TBI-4000. Read the abstract.

Taiga's technology and its applications featured in University of Colorado Cancer Center Quarterly Update.

More News